Two cases of Takayasu's arteritis occurring under anti-TNF therapy.

Abstract

Takayasu's arteritis is a granulomatous, large vessel vasculitis that affects the aorta, its major branches and the pulmonary arteries. Compelling evidence exists to support the notion that Takayasu's arteritis is a T-cell mediated process and that tumor necrosis factor alpha (TNFa) is an important factor in the pathogenesis of this disease. Moreover, encouraging results from recent studies support the use of anti-TNFa therapy for relapsing or resistant cases of Takayasu's arteritis. Here, however, we describe the case of two patients: one with seropositive rheumatoid arthritis, the other with HLA-B27 negative spondylarthropathy, who developed Takayasu's arteritis during treatment with TNFa inhibitors (adalimumab and golimumab respectively). This is the first report of Takayasu's arteritis in rheumatic patients under TNFa blocking agents which suggests the presence of different pathogenetic mechanism in a subgroup of patients with Takayasu's arteritis, as well as a potential role of TNFa blockers as triggers of this disease in some cases.

• Authors: Nicola Mariani, Alexander So, Bérengère Aubry-Rozier
• Journal: Joint bone spine (Joint Bone Spine) Vol. 80 Issue 2 Pg. 211-3 (Mar 2013) ISSN: 1778-7254 [Electronic] France
• PMID: 22999907 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2012 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antirheumatic Agents
• Tumor Necrosis Factor-alpha
• golimumab
• Adalimumab

Topics

• Adalimumab
• Adult
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Antirheumatic Agents (therapeutic use)
• Arthritis, Rheumatoid (complications, drug therapy)
• Drug Resistance
• Female
• Humans
• Spondylarthropathies (complications, drug therapy)
• Takayasu Arteritis (complications, diagnosis, drug therapy)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)